Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment
Xi Zhu1, Yingjie Xu2, Luisa M Solis3
1Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; West China School of Pharmacy, Sichuan University, Chengdu 610041, China;
Abstract:
RNA interference (RNAi) represents a promising strategy for identification and validation of putative therapeutic targets and for treatment of a myriad of important human diseases including cancer. However, the effective systemic in vivo delivery of small interfering RNA (siRNA) to tumors remains a formidable challenge. Using a robust self-assembly strategy, we develop a unique nanoparticle (NP) platform composed of a solid polymer/cationic lipid hybrid core and a lipid-poly(ethylene glycol) (lipid-PEG) shell for systemic siRNA delivery. The new generation lipid-polymer hybrid NPs are small and uniform, and can efficiently encapsulate siRNA and control its sustained release. They exhibit long blood circulation (t1/2 ∼ 8 h), high tumor accumulation, effective gene silencing, and negligible in vivo side effects. With this RNAi NP, we delineate and validate the therapeutic role of Prohibitin1 (PHB1), a target protein that has not been systemically evaluated in vivo due to the lack of specific and effective inhibitors, in treating non-small cell lung cancer (NSCLC) as evidenced by the drastic inhibition of tumor growth upon PHB1 silencing. Human tissue microarray analysis also reveals that high PHB1 tumor expression is associated with poorer overall survival in patients with NSCLC, further suggesting PHB1 as a therapeutic target. We expect this long-circulating RNAi NP platform to be of high interest for validating potential cancer targets in vivo and for the development of new cancer therapies.
Insights
A novel nanoparticle platform enables effective systemic delivery of small interfering RNA (siRNA) for cancer therapy. This technology validates Prohibitin1 as a therapeutic target in non-small cell lung cancer, showing significant tumor growth inhibition.
Area of Science:
- Biotechnology
- Nanomedicine
- Molecular Biology
Background:
- RNA interference (RNAi) offers therapeutic potential but faces challenges in systemic delivery of small interfering RNA (siRNA) to tumors.
- Developing effective delivery systems is crucial for translating RNAi into clinical applications for diseases like cancer.
Purpose of the Study:
- To develop a novel nanoparticle (NP) platform for efficient systemic siRNA delivery.
- To validate Prohibitin1 (PHB1) as a therapeutic target in non-small cell lung cancer (NSCLC) using the developed RNAi NP system.
Main Methods:
- A self-assembly strategy was used to create lipid-polymer hybrid nanoparticles with a solid core and lipid-PEG shell for siRNA encapsulation and controlled release.
- The developed RNAi NPs were evaluated for blood circulation time, tumor accumulation, gene silencing efficacy, and in vivo side effects.
- PHB1's role in NSCLC was investigated by silencing its expression using the RNAi NPs, and its correlation with patient survival was analyzed via tissue microarray.
Main Results:
- The lipid-polymer hybrid NPs demonstrated small, uniform size, efficient siRNA encapsulation, sustained release, long blood circulation (t1/2 ≈ 8 h), and high tumor accumulation.
- Effective gene silencing of PHB1 was achieved, leading to significant inhibition of non-small cell lung cancer tumor growth.
- High PHB1 expression in human NSCLC tissues correlated with poorer patient survival, supporting PHB1 as a viable therapeutic target.
Conclusions:
- The developed long-circulating RNAi NP platform is effective for systemic siRNA delivery, gene silencing, and in vivo target validation.
- Prohibitin1 is identified as a promising therapeutic target for non-small cell lung cancer treatment.
- This NP platform holds significant potential for advancing cancer therapy development and target validation.
